Total Pageviews

5/30/2013

Introducing the WarFairy P-15 3D-Printed AR Stock

Introducing the WarFairy P-15 3D-Printed AR Stock

WarFairy_P-15_Mockup-1
The 3D printed Liberator pistol may be gone, but it is not forgotten. Even with the Department of State bringing down the banhammer on Defense Distributed’s distribution of the plans online, there can be no stopping the continued development of this new branch of firearms technology, by Cody Wilson or anyone else.
The new WarFairy P-15 AR-15 stock by “Shanrilivan” is proof of that. Part AR-15, part FN P90 the P-15 stock is a modular design that allows you to put together a full-size stock with a custom length of pull even on small, non-commercial 3D printers.
One of the primary limitations on hobby-level 3D printing is object scale. While some inexpensive 3D printers like the LulzBot TAZ can print relatively large objects, many non-commercial 3D printers are limited to much smaller print jobs.
Exploded_View
The P-15 gets around scale limitations by being composed of smaller stock parts that are later glued together to make the complete stock. The stock compliments a 3D-printed lower receiver but would work with any standard AR.
Another difference between this stock and most other AR stock designs is that it sports an integrated buffer tube; the stock is the buffer tube, including an extension that passes through a lower receiver’s buffer tower.
It’s a thumbhole stock that connects the pistol grip to the buffer tube. This is a particularly well thought-out design that reinforces the buffer extension, the weakest spot of an AR lower receiver and an especially vulnerable part of a 3D-printed lower.
WarFairy_P-15_Mockup
The first DefDist/Wiki Weapon 3D-printed “firearm” was a 3D-printed lower receiver paired with an AR-57 upper receiver. The lower withstood five direct-blowback impacts before breaking apart on the sixth,right at the buffer tower.
Later on, Defense Distributed developed an improved 3D-printed lower receiver that would withstand sustained fire and rigorous use. While this stock is a far cry from a complete rifle, it’s clear that in the future only a small number of manufactured parts will be necessary to complete an AR-15 rifle.
On the one hand, this is just a 3D-printed stock. On the other, however, is something more important. 3D printing has its limitations, material properties that cannot be improved on without a major shift in the underlying technology. This stock accepts those limitation and works around them, highlighting the fact that you can quiet an individual but not the whole 3D printing community.
This technology is freely available and will continue to adapt and improve. If you want to try out the P-15 stock, you can download it at Github. Shanrilivan has stated that a P-15 handguard is also in the works as well as a single-piece P-90-style AR-15 lower receiver/stock unit called the Charon.
WarFairy_P-15_Mockup-2

1 comment:

  1. FDA-approved treatment for advanced multiple myeloma pomalidomide


    Pomalidomide has been approved for use in the treatment received at least two kinds (including lenalidomide and bortezomib) still occurs after disease progression, as well as for the treatment of non-response, and in the last 60 days of occurrence of a treatment for multiple myeloma disease progression patients.

    "Pomalyst (pomalidomide) is the second lenalidomide and thalidomide allowed after the first three kinds of such immunomodulatory drugs, and is a past year approved for the treatment of multiple myeloma in the first two kinds of drugs." U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of blood and oncology products, Dr. Richard Pazdur said in a statement: "the approval of other drugs ineffective ha un which brings new treatment option."

    Pomalidomide designed as an orphan drug by drug approved by the FDA accelerated approval procedures listed in order to verify the manufacturer to carry out more research efficacy and safety at the same time, so that patients can get earlier this promising new drug.

    The drug's safety and efficacy in an included 221 cases of relapsed or refractory multiple myeloma patients in clinical trials has been verified, the group of patients randomized to receive pomalidomide monotherapy or pomalidomide + low-dose dexamethasone . The results show that in the receiving pomalidomide monotherapy patients, 7.4% had an objective response, the response to maintain the median time not yet reached. In an interview with pomalidomide + low-dose dexamethasone-treated patients, 29% had an objective response, the response to maintain the median time over seven months.

    Common side effects include neutropenia, fatigue, weakness, anemia, constipation, diarrhea, thrombocytopenia, upper respiratory tract infection, back pain, and fever. Pomalidomide with a boxed warning that the drug can cause blood clots, and because can lead to serious, life-threatening birth defects in pregnant women and disabled.

    Only through Pomalyst risk evaluation and mitigation strategy (REMS) program to get pomalidomide. Lenalidomide and thalidomide has a similar REMS.



    Medchemexpress Can provide the above product,its website:www.medchemexpress.com



    Lenvatinib
    MGCD-265
    Pazopanib Hydrochloride
    Vatalanib
    Cabozantinib S-malate
    Ponatinib
    CP-673451
    KRN-633
    Cabozantinib
    Regorafenib hydrochloride

    ReplyDelete